Britain has one of the highest melanoma rates in Europe and one of the lowest rates of daily sunscreen use. The two facts are not unrelated. Why are we still not talking about this, and what will it take to change?
A Nation That Mistrusts the Sun
There is something almost poignant about the British relationship with sunscreen. In a country where the sun is so reliably absent that its appearance is treated as a public event, the idea of applying UV protection every morning feels, to many people, faintly absurd. Sunscreen is for holidays. Sunscreen is for Spain. Sunscreen is for the kind of blazing days that arrive once a decade and prompt the tabloids to run front-page headlines about the hottest June since records began.
The medical reality could not be more different. The UK has one of the highest rates of melanoma in Europe. According to Cancer Research UK, around 16,000 new melanoma cases are diagnosed annually, making it the fifth most common cancer in the country. Rates have quadrupled since the 1970s. And while melanoma is linked to multiple risk factors including genetic predisposition and history of sunburn, UV exposure (including the low-grade cumulative exposure of daily life, not just sunny holidays) is the dominant environmental driver.
UV radiation, critically, is present in the UK 365 days a year. The UVA component of sunlight, which penetrates more deeply into the skin and is primarily responsible for photoageing and a significant proportion of melanoma risk, passes through cloud cover and glass. It is present in the diffuse grey light of a January morning as it is in the direct sun of an August afternoon.
Why the Message Isn’t Landing
Public health messaging around sunscreen in the UK has historically been almost exclusively focused on visible sun exposure: the beach, the garden on a hot day, the outdoor music festival. The messaging has been primarily about avoiding sunburn, which is caused by UVB radiation and is a real risk factor for skin cancer, rather than about the cumulative, daily UVA exposure that most people in Britain are receiving without any conscious awareness of it.
This creates a significant gap. A person who never burns, who sits indoors in a glass-fronted office five days a week, who walks to and from the tube through a grey October, may feel entirely exempt from sunscreen advice. They are not.
The medical community has been consistent but not loud enough. Dermatologists and oncologists regularly recommend year-round SPF use to their patients. But the frequency with which this advice reaches the general population through mainstream media, beauty coverage or public health campaigns is remarkably low compared to the magnitude of the issue.
“UVA passes through cloud cover and glass. It is present in January as it is in August. The idea that sunscreen is only for holidays is not just wrong; it is genuinely dangerous.”
The Beauty Industry’s Role
The sunscreen gap in the UK is partly a public health failure and partly a beauty industry failure. For decades, SPF was an afterthought in skincare, a reluctantly included ingredient in moisturisers, often at concentrations too low to provide meaningful protection, and almost never the primary focus of a product.
This has changed significantly in the past five years. The Korean beauty influence introduced high-SPF, cosmetically elegant sunscreens to a British market accustomed to the chalky, greasy textures associated with older formulations. Skincare influencers, including a generation of dermatologists who built substantial followings on social media, began placing SPF at the top of the skincare hierarchy, not as a seasonal product but as the cornerstone of any daily regime.
The results are visible in the market. Sales of standalone facial SPF products in the UK have grown substantially year-on-year since 2020. British consumers are, slowly, beginning to incorporate sunscreen into their daily routines in a way that is qualitatively different from the holiday-sunscreen habit. But progress remains uneven, and the demographic gaps are significant: research consistently finds that men use sunscreen far less regularly than women, that uptake decreases with age rather than increasing, and that price is a meaningful barrier in lower-income demographics.
The Skin Tone Gap
The sunscreen conversation in the UK has an additional problem: it has historically been conducted almost entirely with white skin in mind, in a country where more than 18% of the population now identifies as non-white.
While the melanin in darker skin tones does provide some additional UV protection (a natural SPF equivalent of roughly 13 for deeply melanated skin, compared to 3 to 4 for fair skin) this does not eliminate skin cancer risk. What it does alter is the presentation: skin cancers in darker skin tones are more likely to appear on areas with less sun exposure, are frequently diagnosed at a later stage, and carry a worse prognosis as a result. Melanoma in darker skin is underdiagnosed in the UK, partly because public health messaging has constructed it as primarily a white skin condition.
Additionally, the cosmetic barrier to sunscreen use is higher for darker skin tones. White-cast formulations, still depressingly common in mineral sunscreens, are not acceptable on melanated skin. Tinted SPF options remain limited in the deeper shade range. The industry’s failure to develop and market effective, cosmetically elegant sunscreens for darker skin is a real access issue, not a trivial one.
What Better Looks Like
The countries with the most effective sunscreen cultures (Australia, South Korea, Japan) share certain characteristics: year-round public health messaging that decouples SPF from ‘sunny weather’; cosmetically sophisticated formulations that people actually enjoy using; cultural normalisation of UV protection as a daily basic rather than a seasonal precaution; and, in Australia’s case, decades of aggressive public health campaigning that has genuinely shifted behaviour.
The UK can learn from all of these. But it requires a level of public health commitment that acknowledges the scale of the problem: 16,000 melanoma diagnoses a year, rising rates, and a population that still broadly believes sunscreen is optional between October and April.
Daily SPF use is the single most evidence-supported intervention available for both the prevention of skin cancer and the reduction of visible skin ageing. It is not complicated. It is not expensive, adequate protection can be achieved for less than £10 a month. It is, however, entirely dependent on people actually doing it. The conversation we need to have is not about the best luxury SPF serum. It is about whether the British public understands, at a basic level, that UV radiation is a year-round, daily reality and that protection from it is not optional. Right now, the answer is largely no.